A subsidiary of OBI pharma which established in 2020. OBIGEN pharma is the first biotech startup company in Taiwan that engages in the research, development, production and manufacturing of Botunilum toxin - OBI-858. The molecular structure of OBI-858 is a special toxin protein with a molecular weight of 760kDa, which is produced by the botulinum toxin type A bacteria during its fermentation. Results of Phase I clinica l trial showed the product was safe and well-tolerated. OBIGEN cooperated with Taiwan CDC and built an API plant in the Zhubei Biomedical Science Park that meets the standard of the international organization ( PIC/s GMP) for the inspection of pharmaceutical product sand the production of APIs with clinical and commercialization purposes. OBIGEN will soon conduct Phase II and III clinical trials in Taiwan, with the goal of obtaining BLA approval in 2025 and plan to launch in Taiwan and Asia countries, and later develop other key markets through strategic partners.